{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T14:59:48Z","timestamp":1792249188088,"version":"4.4.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T00:00:00Z","timestamp":1716163200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T00:00:00Z","timestamp":1716163200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s40259-024-00660-7","type":"journal-article","created":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T10:01:24Z","timestamp":1716199284000},"page":"487-497","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Antibody-Drug Conjugates as Novel Therapeutic Agents for Non-Small Cell Lung Carcinoma with or without Alterations in Oncogenic Drivers"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3486-8505","authenticated-orcid":false,"given":"Laura Bender","family":"Somme","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Chouaid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabien","family":"Moinard-Butot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Baptiste","family":"Barbe-Richaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Greillier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Schott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,20]]},"reference":[{"key":"660_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clinicians. 2023;73:17\u201348.","journal-title":"CA Cancer J Clinicians."},{"key":"660_CR2","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1913662","volume":"382","author":"SS Ramalingam","year":"2020","unstructured":"Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020;382:41\u201350.","journal-title":"N Engl J Med"},{"key":"660_CR3","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1016\/j.annonc.2020.04.478","volume":"31","author":"T Mok","year":"2020","unstructured":"Mok T, Camidge DR, Gadgeel SM, Rosell R, Dziadziuszko R, Kim D-W, et al. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study. Ann Oncol. 2020;31:1056\u201364.","journal-title":"Ann Oncol"},{"key":"660_CR4","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","volume":"378","author":"L Gandhi","year":"2018","unstructured":"Gandhi L, Rodr\u00edguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al. Pembrolizumab plus chemotherapy in metastatic non\u2013small-cell lung cancer. N Engl J Med. 2018;378:2078\u201392.","journal-title":"N Engl J Med"},{"key":"660_CR5","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1200\/JCO.21.02885","volume":"41","author":"G De Castro","year":"2023","unstructured":"De Castro G, Kudaba I, Wu Y-L, Lopes G, Kowalski DM, Turna HZ, et al. Five-year outcomes with pembrolizumab versus chemotherapy as first-line therapy in patients with non\u2013small-cell lung cancer and programmed death ligand-1 tumor proportion score \u22651% in the KEYNOTE-042 study. J Clin Oncol. 2023;41:1986\u201391.","journal-title":"J Clin Oncol"},{"key":"660_CR6","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/S0140-6736(19)31774-X","volume":"394","author":"CH Chau","year":"2019","unstructured":"Chau CH, Steeg PS, Figg WD. Antibody\u2013drug conjugates for cancer. Lancet. 2019;394:793\u2013804.","journal-title":"Lancet"},{"key":"660_CR7","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","volume":"384","author":"A Bardia","year":"2021","unstructured":"Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med. 2021;384:1529\u201341.","journal-title":"N Engl J Med"},{"key":"660_CR8","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/j.annonc.2021.03.005","volume":"32","author":"A Bardia","year":"2021","unstructured":"Bardia A, Messersmith WA, Kio EA, Berlin JD, Vahdat L, Masters GA, et al. Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I\/II IMMU-132-01 basket trial. Ann Oncol. 2021;32:746\u201356.","journal-title":"Ann Oncol"},{"key":"660_CR9","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1200\/JCO.20.03489","volume":"39","author":"ST Tagawa","year":"2021","unstructured":"Tagawa ST, Balar AV, Petrylak DP, Kalebasty AR, Loriot Y, Fl\u00e9chon A, et al. TROPHY-U-01: a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors. J Clin Oncol. 2021;39:2474\u201385.","journal-title":"J Clin Oncol"},{"key":"660_CR10","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMoa1914510","volume":"382","author":"S Modi","year":"2020","unstructured":"Modi S, Saura C, Yamashita T, Park YH, Kim S-B, Tamura K, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med. 2020;382:610\u201321.","journal-title":"N Engl J Med"},{"key":"660_CR11","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1056\/NEJMoa2112431","volume":"386","author":"BT Li","year":"2022","unstructured":"Li BT, Smit EF, Goto Y, Nakagawa K, Udagawa H, Mazi\u00e8res J, et al. Trastuzumab deruxtecan in HER2-mutant non\u2013small-cell lung cancer. N Engl J Med. 2022;386:241\u201351.","journal-title":"N Engl J Med"},{"key":"660_CR12","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1111\/cas.12966","volume":"107","author":"Y Ogitani","year":"2016","unstructured":"Ogitani Y, Hagihara K, Oitate M, Naito H, Agatsuma T. Bystander killing effect of ds -8201a, a novel anti-human epidermal growth factor receptor 2 antibody\u2013drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci. 2016;107:1039\u201346.","journal-title":"Cancer Sci"},{"key":"660_CR13","doi-asserted-by":"publisher","first-page":"713","DOI":"10.3390\/cancers15030713","volume":"15","author":"TD Nguyen","year":"2023","unstructured":"Nguyen TD, Bordeau BM, Balthasar JP. Mechanisms of ADC toxicity and strategies to increase ADC tolerability. Cancers. 2023;15:713.","journal-title":"Cancers"},{"key":"660_CR14","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","volume":"7","author":"Z Fu","year":"2022","unstructured":"Fu Z, Li S, Han S, Shi C, Zhang Y. Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy. Sig Transduct Target Ther. 2022;7:93.","journal-title":"Sig Transduct Target Ther."},{"key":"660_CR15","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.3390\/cancers13071571","volume":"13","author":"J Radocha","year":"2021","unstructured":"Radocha J, Van De Donk NWCJ, Weisel K. Monoclonal antibodies and antibody drug conjugates in multiple myeloma. Cancers. 2021;13:1571.","journal-title":"Cancers"},{"key":"660_CR16","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1182\/blood-2013-10-535088","volume":"123","author":"Y-T Tai","year":"2014","unstructured":"Tai Y-T, Mayes PA, Acharya C, Zhong MY, Cea M, Cagnetta A, et al. Novel anti\u2013B cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood. 2014;123:3128\u201338.","journal-title":"Blood"},{"key":"660_CR17","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1158\/1078-0432.CCR-14-2093","volume":"21","author":"H Uppal","year":"2015","unstructured":"Uppal H, Doudement E, Mahapatra K, Darbonne WC, Bumbaca D, Shen B-Q, et al. Potential mechanisms for thrombocytopenia development with trastuzumab emtansine (T-DM1). Clin Cancer Res. 2015;21:123\u201333.","journal-title":"Clin Cancer Res"},{"key":"660_CR18","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1159\/000522206","volume":"89","author":"D Dum","year":"2022","unstructured":"Dum D, Taherpour N, Menz A, H\u00f6flmayer D, V\u00f6lkel C, Hinsch A, et al. Trophoblast cell surface antigen 2 expression in human tumors: a tissue microarray study on 18,563 tumors. Pathobiology. 2022;89:245\u201358.","journal-title":"Pathobiology"},{"issue":"29","key":"660_CR19","doi-asserted-by":"publisher","first-page":"4678","DOI":"10.1200\/JCO.23.00059","volume":"41","author":"T Shimizu","year":"2023","unstructured":"Shimizu T, Sands J, Yoh K, Spira A, Garon EB, Kitazono S, et al. First-in-human, phase I dose-escalation and dose-expansion study of trophoblast cell-surface antigen 2\u2013directed antibody-drug conjugate datopotamab deruxtecan in non\u2013small-cell lung cancer: TROPION-PanTumor01. J Clin Oncol. 2023;41(29):4678\u201387.","journal-title":"J Clin Oncol"},{"key":"660_CR20","doi-asserted-by":"publisher","first-page":"28725","DOI":"10.18632\/oncotarget.15647","volume":"8","author":"K Inamura","year":"2017","unstructured":"Inamura K, Yokouchi Y, Kobayashi M, Ninomiya H, Sakakibara R, Subat S, et al. Association of tumor TROP2 expression with prognosis varies among lung cancer subtypes. Oncotarget. 2017;8:28725\u201335.","journal-title":"Oncotarget"},{"key":"660_CR21","doi-asserted-by":"publisher","first-page":"S755","DOI":"10.1016\/j.annonc.2023.09.2348","volume":"34","author":"L Paz-Ares","year":"2023","unstructured":"Paz-Ares L, Ahn M-J, Lisberg AE, Kitazono S, Cho BC, Blumenschein G, et al. 1314MO TROPION-Lung05: datopotamab deruxtecan (Dato-DXd) in previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs). Ann Oncol. 2023;34:S755\u20136.","journal-title":"Ann Oncol"},{"key":"660_CR22","doi-asserted-by":"publisher","first-page":"S1305","DOI":"10.1016\/j.annonc.2023.10.061","volume":"34","author":"M-J Ahn","year":"2023","unstructured":"Ahn M-J, Lisberg A, Paz-Ares L, Cornelissen R, Girard N, Pons-Tostivint E, et al. LBA12 Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced\/metastatic (adv\/met) non-small cell lung cancer (NSCLC): results of the randomized phase III study TROPION-Lung01. Ann Oncol. 2023;34:S1305\u20136.","journal-title":"Ann Oncol"},{"issue":"16 Suppl","key":"660_CR23","doi-asserted-by":"publisher","first-page":"9004","DOI":"10.1200\/JCO.2023.41.16_suppl.9004","volume":"41","author":"Y Goto","year":"2023","unstructured":"Goto Y, Su W-C, Levy BP, Rixe O, Yang T-Y, Tolcher AW, et al. TROPION-Lung02: Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) in advanced non-small cell lung cancer (aNSCLC). J Clin Oncol. 2023;41(16 Suppl):9004.","journal-title":"J Clin Oncol"},{"key":"660_CR24","doi-asserted-by":"publisher","first-page":"2790","DOI":"10.1200\/JCO.2016.72.1894","volume":"35","author":"RS Heist","year":"2017","unstructured":"Heist RS, Guarino MJ, Masters G, Purcell WT, Starodub AN, Horn L, et al. Therapy of advanced non\u2013small-cell lung cancer with an SN-38-anti-trop-2 drug conjugate Sacituzumab Govitecan. J Clin Oncol. 2017;35:2790\u20137.","journal-title":"J Clin Oncol"},{"issue":"16 Suppl","key":"660_CR25","doi-asserted-by":"publisher","first-page":"9114","DOI":"10.1200\/JCO.2023.41.16_suppl.9114","volume":"41","author":"W Fang","year":"2023","unstructured":"Fang W, Cheng Y, Chen Z, Wang W, Yin Y, Li Y, et al. SKB264 (TROP2-ADC) for the treatment of patients with advanced NSCLC: efficacy and safety data from a phase 2 study. J Clin Oncol. 2023;41(16 Suppl):9114.","journal-title":"J Clin Oncol"},{"key":"660_CR26","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.jtho.2017.10.032","volume":"13","author":"K Hotta","year":"2018","unstructured":"Hotta K, Aoe K, Kozuki T, Ohashi K, Ninomiya K, Ichihara E, et al. A phase II study of trastuzumab emtansine in HER2-positive non-small cell lung cancer. J Thorac Oncol. 2018;13:273\u20139.","journal-title":"J Thorac Oncol"},{"key":"660_CR27","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1200\/JCO.2018.77.9777","volume":"36","author":"BT Li","year":"2018","unstructured":"Li BT, Shen R, Buonocore D, Olah ZT, Ni A, Ginsberg MS, et al. Ado-trastuzumab emtansine for patients with HER2 -mutant lung cancers: results from a phase II basket trial. J Clin Oncol. 2018;36:2532\u20137.","journal-title":"J Clin Oncol"},{"key":"660_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.02.003","author":"HA Yu","year":"2024","unstructured":"Yu HA, Baik C, Kim D-W, Johnson ML, Hayashi H, Nishio M, et al. Translational insights and overall survival in the U31402-A-U102 study of patritumab deruxtecan (HER3-DXd) in EGFR-mutated NSCLC. Ann Oncol. 2024. https:\/\/doi.org\/10.1016\/j.annonc.2024.02.003.","journal-title":"Ann Oncol"},{"key":"660_CR29","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1158\/2159-8290.CD-21-0715","volume":"12","author":"PA J\u00e4nne","year":"2022","unstructured":"J\u00e4nne PA, Baik C, Su W-C, Johnson ML, Hayashi H, Nishio M, et al. Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated non-small cell lung cancer. Cancer Discov. 2022;12:74\u201389.","journal-title":"Cancer Discov"},{"key":"660_CR30","doi-asserted-by":"publisher","first-page":"5363","DOI":"10.1200\/JCO.23.01476","volume":"41","author":"HA Yu","year":"2023","unstructured":"Yu HA, Goto Y, Hayashi H, Felip E, Chih-Hsin Yang J, Reck M, et al. HERTHENA-Lung01, a phase II trial of patritumab deruxtecan (HER3-DXd) in epidermal growth factor receptor-mutated non\u2013small-cell lung cancer after epidermal growth factor receptor tyrosine kinase inhibitor therapy and platinum-based chemotherapy. J Clin Oncol. 2023;41:5363\u201375.","journal-title":"J Clin Oncol"},{"issue":"15 Suppl","key":"660_CR31","doi-asserted-by":"publisher","first-page":"9505","DOI":"10.1200\/JCO.2020.38.15_suppl.9505","volume":"38","author":"A Gazzah","year":"2020","unstructured":"Gazzah A, Ricordel C, Cousin S, Cho BC, Calvo E, Kim TM, et al. Efficacy and safety of the antibody-drug conjugate (ADC) SAR408701 in patients (pts) with non-squamous non-small cell lung cancer (NSQ NSCLC) expressing carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5). J Clin Oncol. 2020;38(15 Suppl):9505.","journal-title":"J Clin Oncol"},{"key":"660_CR32","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.cllc.2020.09.013","volume":"22","author":"SN Waqar","year":"2021","unstructured":"Waqar SN, Redman MW, Arnold SM, Hirsch FR, Mack PC, Schwartz LH, et al. A phase II study of telisotuzumab vedotin in patients with c\u2013MET-positive stage IV or recurrent squamous cell lung cancer (LUNG-MAP sub-study S1400K, NCT03574753). Clin Lung Cancer. 2021;22:170\u20137.","journal-title":"Clin Lung Cancer"},{"issue":"16 Suppl","key":"660_CR33","doi-asserted-by":"publisher","first-page":"9016","DOI":"10.1200\/JCO.2022.40.16_suppl.9016","volume":"40","author":"DR Camidge","year":"2022","unstructured":"Camidge DR, Bar J, Horinouchi H, Goldman JW, Moiseenko FV, Filippova E, et al. Telisotuzumab vedotin (Teliso-V) monotherapy in patients (pts) with previously treated c-Met\u2013overexpressing (OE) advanced non-small cell lung cancer (NSCLC). J Clin Oncol. 2022;40(16 Suppl):9016.","journal-title":"J Clin Oncol"},{"key":"660_CR34","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","volume":"367","author":"S Verma","year":"2012","unstructured":"Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367:1783\u201391.","journal-title":"N Engl J Med"},{"key":"660_CR35","doi-asserted-by":"publisher","first-page":"165","DOI":"10.3322\/caac.21705","volume":"72","author":"P Tarantino","year":"2022","unstructured":"Tarantino P, Carmagnani Pestana R, Corti C, Modi S, Bardia A, Tolaney SM, et al. Antibody\u2013drug conjugates: smart chemotherapy delivery across tumor histologies. CA Cancer J Clinicians. 2022;72:165\u201382.","journal-title":"CA Cancer J Clinicians."},{"key":"660_CR36","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S1470-2045(18)30859-3","volume":"20","author":"JS De Bono","year":"2019","unstructured":"De Bono JS, Concin N, Hong DS, Thistlethwaite FC, Machiels J-P, Arkenau H-T, et al. Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1\u20132 trial. Lancet Oncol. 2019;20:383\u201393.","journal-title":"Lancet Oncol"},{"key":"660_CR37","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1200\/JCO.19.02044","volume":"38","author":"J Rosenberg","year":"2020","unstructured":"Rosenberg J, Sridhar SS, Zhang J, Smith D, Ruether D, Flaig TW, et al. EV-101: a phase I study of single-agent enfortumab vedotin in patients with nectin-4\u2013positive solid tumors, including metastatic urothelial carcinoma. J Clin Oncol. 2020;38:1041\u20139.","journal-title":"J Clin Oncol"},{"key":"660_CR38","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/S1470-2045(15)70128-2","volume":"16","author":"MCA Palanca-Wessels","year":"2015","unstructured":"Palanca-Wessels MCA, Czuczman M, Salles G, Assouline S, Sehn LH, Flinn I, et al. Safety and activity of the anti-CD79B antibody\u2013drug conjugate polatuzumab vedotin in relapsed or refractory B cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study. Lancet Oncol. 2015;16:704\u201315.","journal-title":"Lancet Oncol"},{"key":"660_CR39","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1002\/cncr.34507","volume":"129","author":"Y Zhu","year":"2023","unstructured":"Zhu Y, Liu K, Wang K, Zhu H. Treatment-related adverse events of antibody\u2013drug conjugates in clinical trials: a systematic review and meta-analysis. Cancer. 2023;129:283\u201395.","journal-title":"Cancer"}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-024-00660-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-024-00660-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-024-00660-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,14]],"date-time":"2024-07-14T22:16:21Z","timestamp":1720995381000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-024-00660-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,20]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["660"],"URL":"https:\/\/doi.org\/10.1007\/s40259-024-00660-7","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,20]]},"assertion":[{"value":"22 April 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No external funding was used in the preparation of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Laura Bender Somme: MSD, Novartis, Daiichi Sankyo, Takeda. Christos Chouaid: AstraZeneca, BI, GSK, Roche, Sanofi Aventis, BMS, MSD, Lilly, Novartis, Pfizer, Takeda, Bayer and Amgen. Roland Schott: Bristol-Myers Squibb\/Celgene, Roche, AstraZeneca. Laurent Greillier: BMS, MSD, Takeda, Pfizer, Roche, Novartis, Amgen, Lilly, Jansen. Fabien Moinard-Butot and Jean-Baptiste Barbe-Richaud declare they have no conflicts of interest that might be relevant to the contents of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"LBS, RS and CC performed the material preparation, data collection and analysis. LBS wrote the first draft of the manuscript. All authors commented on previous versions of the manuscript, and read and approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}